A personalized melanoma vaccine built from each patient's own tumor mutations has advanced to phase III testing alongside checkpoint inhibition, following earlier data showing a substantial reduction in recurrence and death compared with immunotherapy alone. The approach trains the immune system to recognize neoantigens unique to an individual's cancer rather than targeting a shared, population-wide antigen. If confirmed, it marks a shift from uniform cancer protocols to therapy designed around a single tumor's genetic signature.
Key Points
- Individualized mRNA vaccine encodes neoantigens from each patient's own tumor
- Combined with checkpoint inhibition, recurrence risk fell substantially in earlier testing
- Phase III trial tests whether personalized immunotherapy becomes standard melanoma care
Longevity Analysis
Cancer remains one of the dominant drivers of mortality in the second half of life, and the leverage here lies in teaching immune surveillance to distinguish a specific tumor from healthy tissue — precision that broad cytotoxic approaches cannot achieve. The same logic that governs effective prevention applies: identify the exact signal, interpret it correctly, then act on it rather than on a population average. Durable benefit will still depend on the condition of the host immune system, which is shaped long before diagnosis by sleep, metabolic health, and the cumulative exposures a person has eliminated or tolerated.
Original published by Peter Attia MD, by Peter Attia.